Trial Profile
Phase I trial of cannabidiol for the treatment of neonatal hypoxic-ischaemic encephalopathy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2017
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Cerebral ischaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 09 May 2017 Status changed from recruiting to completed, according to a GW Pharmaceuticals media release.
- 05 Dec 2016 Status changed from planning to recruiting, according to a GW Pharmaceuticals media release.
- 05 May 2016 This trial is expected to begin in Q4 2016, according to a GW Pharmaceuticals media release.